Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

synthon bv - pramipeksol - tableta - pramipeksol 0,18 mg / 1 tableta - pramipeksol

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

synthon bv - pramipeksol - tableta - pramipeksol 0,35 mg / 1 tableta - pramipeksol

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

synthon bv - pramipeksol - tableta - pramipeksol 0,35 mg / 1 tableta - pramipeksol

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

synthon bv - pramipeksol - tableta - pramipeksol 0,7 mg / 1 tableta - pramipeksol

Evropska unija - slovenščina - EMA (European Medicines Agency)

archie samiel s.r.o. - klopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotična sredstva - clopidogrel je navedeno pri odraslih za preprečevanje atherothrombotic dogodkov v:bolnike, ki trpijo za miokardni infarkt (od nekaj dni do manj kot 35 dni), ischaemic kap (od 7 dni do manj kot 6 mesecev) ali sedež periferne arterijske bolezni;bolniki, ki trpijo za akutni koronarni sindrom:non-st-segmenta,-dvig akutni koronarni sindrom (nestabilna angina pektoris ali ne-q val-miokardni infarkt), vključno z bolniki, ki opravljajo stent umestitev po perkutani koronarni intervenciji, v kombinaciji z acetilsalicilne kisline (asa);st-segmenta,-dvig akutni miokardni infarkt, v kombinaciji s asa v medicinsko zdravljenih bolnikih, ki izpolnjujejo pogoje za thrombolytic terapija.

Evropska unija - slovenščina - EMA (European Medicines Agency)

csl behring gmbh - humani normalni imunoglobulin (scig) - sindromi imunološke pomanjkljivosti - imunski sera in imunoglobulini, - replacement therapy in adults, children and adolescents (0-18 years) in:- primary immunodeficiency syndromes with impaired antibody production (see section 4. - secondary immunodeficiencies (sid) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (psaf)* or serum igg level of.

Slovenija - slovenščina - Ecolab

ecolab deutschland gmbh -

Evropska unija - slovenščina - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - pramipeksol dihidroklorid monohidrat - restless legs syndrome; parkinson disease - anti-parkinsonska zdravila - zdravilo mirapexin je indicirano za zdravljenje znakov in simptomov idiopatske parkinsonove bolezni, samo (brez levodope) ali v kombinaciji z levodopo, i. v času bolezni, do poznih stopenj, ko se učinek levodope izčrpa ali postane neskladen, pojavijo pa se tudi nihanja terapevtskega učinka (nihanja na koncu odmerka ali "on-off" nihanja). mirapexin je označen za simptomatsko zdravljenje zmerne do hude idiopatsko nemirna-noge sindrom v odmerkih do 0. 54 mg znanja (0. 75 mg soli).

Evropska unija - slovenščina - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - pramipeksol dihidroklorid monohidrat - restless legs syndrome; parkinson disease - anti-parkinsonska zdravila - sifrol je indiciran za zdravljenje znakov in simptomov idiopatske parkinsonove bolezni, sam (brez levodope) ali v kombinaciji z levodopo, i. v času bolezni, čeprav v poznih fazah, ko se učinek levodope izčrpa ali postane neskladen, pojavijo pa se tudi nihanja terapevtskega učinka (nihanja na koncu odmerka ali "on-off" nihanja). sifrol je označen za simptomatsko zdravljenje zmerne do hude idiopatsko nemirna-noge sindrom v odmerkih do 0. 54 mg znanja (0. 75 mg soli).

Evropska unija - slovenščina - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - imunosupresivi - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.